Article
Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
Chinese medical journal - 20 Aug 2007
Yang Yang, Zhang Qi, Cai Chang-jie, Lu Ming-qiang, Li Xi, Jiang Nan, Jiang Hua, Xu Chi, Li Hua, Wang Gen-shu, Yi Shu-hong, Zhang Jian, Zhang Jun-feng, Yi Hui-min, Zhang Ying-cai, Chen Gui-hua
Abstract excerpt
BACKGROUND: The most frequently used therapy for post-transplantation recurrence of hepatitis B virus (HBV) infection is lamivudine, but this drug is associated with a high resistance rate due to YMDD mutant. In preliminary reports, adefovir dipivoxil (ADV) has been shown to have activity against lamivudine-resistant strains of HBV. However, clinical experience in treatment of HBV infection after liver...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.